Duvyzat (givinostat) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD). It regulates gene expression by inhibiting histone deacetylase (HDAC) and delays disease progression. Its unique non-steroidal properties make it the first therapy suitable for all patients with DMD genetic variants.

Duvyzat's role and efficacy

The core value of Duvyzat lies in its therapeutic effect on Duchenne muscular dystrophy, which brings hope to patients by regulating gene expression and improving muscle function.

Targeted treatment mechanism

The main ingredient of Duvyzat is the histone deacetylase (HDAC) inhibitor givinostat hydrochloride monohydrate. The excessive activity of HDAC is closely related to the pathological process of DMD, and Duvyzat inhibits HDAC, regulates gene expression, thereby reducing muscle degeneration and delaying disease progression. This targeted mechanism of action makes it an important breakthrough in the treatment of DMD.

Clinical efficacy

Clinical trials have shown that Duvyzat can significantly improve patients' muscle function and quality of life. The drug is the eighth DMD treatment approved in the United States. It is suitable for patients aged 6 years and above and is effective for all types of genetic variations. Its broad spectrum of efficacy provides treatment opportunities for more DMD patients.

The effects and efficacy of Duvyzat are not only reflected in delaying disease progression, but also in providing patients with longer functional retention through its unique mechanism. This innovative therapy has opened up a new path for DMD treatment.

Basic information about Duvyzat

Understanding the basic information about Duvyzat will help patients and medical professionals better use and manage this drug.

Drug specifications and usage

Duvyzat is an oral suspension with a specification of 140ml, which needs to be taken with food to increase drug absorption. The recommended dose is adjusted according to the patient's weight and is administered twice a day. For example, patients weighing 60 kg and above receive 53.2mg (about 6ml) each time. Platelet count and serum triglyceride levels need to be assessed before treatment to ensure drug safety.

Adverse reactions and precautions

Duvyzat may cause adverse reactions such as thrombocytopenia, diarrhea, and increased serum triglycerides. Patients need to monitor relevant indicators regularly and adjust the dose or stop taking the drug in time when abnormalities occur. In addition, avoid taking it with other drugs that prolong the QTc interval to reduce the risk of arrhythmia.

The basic information of Duvyzat covers multiple aspects from usage to safety, providing patients with comprehensive medication guidance. Rational use of this drug can maximize its therapeutic effect while reducing potential risks.

Dietary habits of patients taking Duvyzat

Dietary habits have an important impact on the efficacy and safety of Duvyzat, and patients need to pay special attention to dietary adjustments.

Dietary recommendations related to drug absorption

Taking Duvyzat with a high-fat meal can increase drug exposure by about 40%, so it is recommended that patients take a moderate amount of fat food when taking the drug to improve drug absorption efficiency. At the same time, avoid taking the drug on an empty stomach to reduce the occurrence of gastrointestinal discomfort.

Dietary management of abnormal lipid metabolism

Since Duvyzat may cause an increase in serum triglycerides, patients should reduce the intake of high-sugar and high-fat foods and increase foods rich in dietary fiber such as whole grains, vegetables and fruits. Monitor blood lipid levels regularly and adjust the diet structure under the guidance of a doctor if necessary.

The eating habits of Duvyzat patients not only affect the efficacy of the drug, but are also closely related to the management of adverse reactions. Through scientific dietary adjustments, patients can better cooperate with treatment and improve their overall health.